Laura Estrada | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Prof. Laura Estrada | Molecular Biology | Best Researcher Award 

Researcher | Physics department University of Buenos Aires | Argentina

Prof. Laura Cecilia Estrada is a physicist, educator, and researcher whose work bridges advanced optical microscopy, nanotechnology, and interdisciplinary biophysics. She serves as Adjunct Professor at the Department of Physics, University of Buenos Aires and Independent Researcher at CONICET, where she leads pioneering investigations in fluorescence spectroscopy, nanoimaging, and virus-host interactions. Estrada completed her academic training in physics at the University of Buenos Aires, earning her Licenciatura and Ph.D. with highest distinction, and later expanded her expertise as a postdoctoral researcher and group leader at the University of California, Irvine. Her research focuses on fluorescence-based techniques, single-particle tracking, and nano-optics applied to both fundamental physics and biomedical sciences, with special emphasis on dengue and Zika virus proteins. Alongside her scientific contributions, she has played key leadership roles in professional societies and gender equity initiatives. Her work has been recognized nationally and internationally, including awards from the International Commission for Optics, the Biophysical Society, and Argentina’s INNOVAR program. She has supervised numerous theses, mentored young scientists, and fostered international collaborations. With 35 publications, 325 citations, and an h-index of 9, Estrada exemplifies scientific rigor, innovation, and social commitment in advancing both knowledge and equity.

Profile: Scopus

Featured Publications

Sallaberry, I., & Estrada, L. Unraveling viral protein-host membrane interaction for dengue and Zika. Biophysical Journal.

Leon, A., Sallaberry, I., Estrada, L., & Scorticati, C. Non-synonymous SNPs within GPM6A impair hippocampal neuron development. Biochimica et Biophysica Acta, 1872(3). Cited by 2.

Salzman, V., & Estrada, L. Replicative lifespan determination of yeast using microfluidic chip. Biology Open, 13(11). Cited by 5.

Gaggioli, E., Estrada, L., & Bruno, O. Boundary layer structures in transport theory. Physical Review E, 110. Cited by 3.

Philipp, N., Gratton, E., & Estrada, L. Protein-membrane interaction via radial FCS. Methods and Applications in Fluorescence, 11(4). Cited by 12.

Gabriel, M., & Estrada, L. Dengue Virus Capsid Protein Dynamics in live cells. Scientific Reports, 10. Cited by 45.

Maria Camprubi Robles | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Maria Camprubi Robles | Molecular Biology | Best Researcher Award 

Research Scientist | Abbott Laboratories | Spain

Dr. Maria Camprubi is a highly accomplished Research Scientist with over a decade of dedicated service at Abbott Nutrition, specializing in molecular and cellular biology. With strong expertise in nutritional science, she has significantly contributed to the development of innovative products that address sarcopenia, chronic disease, and malnutrition across Europe, the Middle East, and Africa. She holds a Ph.D. in Molecular and Cellular Biology, where she built a strong foundation in cellular processes and metabolic regulation. Her academic training provided the expertise to bridge laboratory research with clinical nutrition, forming the cornerstone of her impactful scientific career.  Dr. Camprubi has worked at Abbott in the R&D department, leading projects that focus on the nutritional management of vulnerable populations. Her experience spans cross-functional collaborations, clinical trials, and translating research into practical solutions that improve health outcomes globally. Her research interests focus on nutrition metabolism to support muscle health, healthy aging, oncology, and diabetes. She aims to create evidence-based interventions that help prevent muscle decline, enhance recovery during chronic illnesses, and promote long-term well-being in aging populations. Dr. Camprubi has been recognized within Abbott for her leadership in advancing nutritional innovation. Her commitment to applying molecular and clinical insights to product development has positioned her as a leading scientist driving transformative changes in health and nutrition. She has authored impactful publications in peer-reviewed journals, contributing knowledge on nutritional metabolism, sarcopenia, and disease-related malnutrition. Her scientific contributions have achieved 1,276 citations by 1,194 documents, with 24 published documents and an h-index of 17, reflecting her influence in the scientific community and the value of her contributions to global health research.

Profile: Scopus

Featured Publications

A prospective, observational study of the effect of a high-calorie, high-protein oral nutritional supplement with HMB in an old and malnourished or at-risk-of-malnutrition population with hip fractures: A FracNut study. Nutrients, 16(8)

The vicious cycle of type 2 diabetes mellitus and skeletal muscle atrophy: Clinical, biochemical, and nutritional bases. Nutrients, 16(1), 172

Heng Zhang | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Heng Zhang | Molecular Biology | Best Researcher Award 

Lecturer | Nankai University | China

Dr. Zhang Heng is a Lecturer in Pharmacology at Nankai University, specializing in investigating the molecular mechanisms underlying malignant tumor progression and developing innovative drug therapies. He earned his B.S., M.S., and Ph.D. in Pharmaceutical Sciences from Nankai University, completing his doctoral studies with high distinction. Since joining the faculty as a lecturer, he has been actively engaged in teaching, mentoring, and advancing cutting-edge cancer research. Dr. Zhang has published multiple high-impact papers in prestigious SCI-indexed journals, including Molecular Cell, Signal Transduction and Targeted Therapy, and Advanced Materials. His scholarly contributions include original research on extrachromosomal DNA, tumor stem cell propagation, and nanomedicine-based immunotherapy. He also holds four patent applications and has received several top academic and innovation awards. Through his research and academic leadership, Dr. Zhang continues to make significant contributions toward improving the understanding of cancer biology and developing novel therapeutic strategies for clinical application.

Professional Profile

ORCID

Education

Dr. Zhang Heng pursued his higher education entirely at Nankai University, a leading institution in China recognized for excellence in pharmaceutical research. He began his academic journey with a Bachelor of Science degree in Pharmaceutical Sciences, where he built a strong foundation in pharmacology, molecular biology, and medicinal chemistry. Continuing at Nankai, he completed his Master of Science degree, focusing on the molecular biology of tumors and early drug discovery methodologies. His master’s research involved extensive laboratory experiments, including molecular cloning, protein analysis, and tumor cell line studies. Dr. Zhang then earned his Ph.D. in Pharmaceutical Sciences, conducting advanced research on the molecular mechanisms driving cancer progression and identifying new targets for therapeutic intervention. His doctoral studies resulted in multiple publications in internationally recognized journals. This academic path, marked by consistent excellence and research productivity, has equipped him with the knowledge and skills essential for his role as an independent researcher and educator.

Experience

Following the completion of his doctoral studies, Dr. Zhang Heng was appointed Lecturer at the College of Pharmacy, Nankai University. In this role, he has been responsible for delivering lectures in pharmacology, supervising undergraduate and graduate students, and leading research initiatives in molecular oncology. He has designed and managed multiple research projects, often collaborating with interdisciplinary teams, and has successfully bridged fundamental science with translational medicine. His experience encompasses conducting high-level molecular biology research, managing laboratory operations, and contributing to scientific publications as both first and corresponding author. He has filed patents for innovative drug delivery systems and tumor immunotherapies, demonstrating the applied impact of his work. Beyond laboratory research, Dr. Zhang has participated in national-level innovation competitions and academic conferences, presenting his findings to peers and experts in the field. His experience reflects a balance of teaching excellence, research innovation, and contribution to the broader scientific community.

Research Interest

Dr. Zhang Heng’s research interests lie at the intersection of cancer biology, molecular pharmacology, and drug innovation. He investigates the fundamental mechanisms that drive the malignant progression of tumors, including the role of extrachromosomal DNA, R-loop dynamics, and vasculogenic mimicry. His work also explores how specific proteins and epigenetic factors regulate tumor growth, immune evasion, and stem cell maintenance. In addition to basic research, Dr. Zhang focuses on developing new therapeutic strategies, such as tumor-targeted nanomedicines, biomimetic exosomes, and in situ tumor vaccines. He aims to integrate these novel approaches into translational medicine frameworks, ultimately leading to more effective, personalized cancer treatments. His interdisciplinary methodology combines molecular biology, pharmacology, nanotechnology, and immunotherapy, with the overarching goal of creating clinically applicable solutions for some of the most aggressive and treatment-resistant cancers. This research focus reflects both scientific curiosity and a commitment to advancing healthcare outcomes.

Award

Dr. Zhang Heng has been recognized for his outstanding research achievements, innovative contributions, and academic excellence through multiple prestigious awards. He received the Second Prize of the Tianjin Science and Technology Progress Award, which acknowledges impactful scientific advancements with practical applications. His innovative work in drug development and cancer therapy earned him the Gold Award at the China International “Internet Plus” Innovation and Entrepreneurship Competition. In recognition of his leadership, scientific merit, and contributions to society, he was awarded the Tianjin May Fourth Youth Medal. While a student, Dr. Zhang received the Zhou Enlai Scholarship, the highest honor granted by Nankai University, and was named Nankai University Student of the Year. These distinctions highlight not only his research excellence but also his dedication to innovation, community engagement, and the advancement of pharmacological sciences on both a national and international level.

Top Noted Publication

Dr. Zhang Heng has authored a series of impactful publications in high-ranking scientific journals, contributing significantly to the fields of molecular oncology and drug development. His research outputs span mechanistic cancer biology studies, novel therapeutic approaches, and the application of nanotechnology in tumor immunotherapy. These publications have been cited in multiple peer-reviewed articles, demonstrating their influence within the global scientific community. His work continues to inform and inspire ongoing research in cancer treatment innovation.

Publications list (single-line prompt):

Title: Extrachromosomal DNA biogenesis is dependent on DNA looping and religation by YY1–Lig3–PARylation complex
Journal: Molecular Cell
Year: 2025

Title: MTA2 triggered R-loop trans-regulates BDH1-mediated β-hydroxybutyrylation and potentiates propagation of hepatocellular carcinoma stem cells
Journal: Signal Transduction and Targeted Therapy
Year: 2021

Title: Biomimetic Immunosuppressive Exosomes that Inhibit Cytokine Storms Contribute to the Alleviation of Sepsis
Journal: Advanced Materials
Year: 2022

Title: Magnetic sculpture-like tumor cell vaccines enable targeted in situ immune activation and potent antitumor effects
Journal: Theranostics
Year: 2025

Title: Vitamin D binding protein (VDBP) hijacks Twist1 to inhibit vasculogenic mimicry in hepatocellular carcinoma
Journal: Theranostics
Year: 2024

Conclusion

Dr. Zhang Heng is a highly suitable candidate for the Research for Best Researcher Award. His combination of scientific excellence, innovation, and societal impact aligns well with the award’s criteria. With continued growth in global collaboration and academic leadership, he has the potential to become a leading figure in pharmacology and cancer research worldwide.

 

Baran SEVEN | Molecular Biology | Best Paper Award

Published on by Molecular Biologist

Dr. Baran Seven | Molecular Biology | Best Paper Award

Doctorate | TST Fittings and Medical Devices Industry and Trade | Turkey

Dr. Baran Seven is a committed biologist whose academic journey reflects a deep focus on toxicology, molecular biology, and environmental sciences. He earned his undergraduate, master’s, and doctoral degrees in Biology from Giresun University. His research has primarily involved investigating the toxicological effects of various chemical compounds on in vivo models, particularly Swiss albino mice. Throughout his academic progression, he has actively participated in multiple national and international scientific projects, often examining the protective effects of natural plant extracts against induced toxicities. Dr. Seven has published extensively in peer-reviewed journals and has presented his findings at numerous scientific conferences. His work demonstrates an interdisciplinary approach, blending physiological, genetic, and biochemical methods to assess and mitigate toxicity. With a strong background in both laboratory research and academic collaboration, Dr. Seven continues to contribute significantly to the fields of environmental toxicology and biomedical sciences.

Professional Profile

Scopus

Education

Dr. Baran Seven completed his entire academic training in Biology at Giresun University, Turkey. He obtained his Bachelor’s degree in 2013, followed by a Master’s degree in 2015 under the supervision of Associate Professor Kültiğin Çavuşoğlu and Professor Kürşad Yapar. His master’s thesis, titled “Albino farelerde paraben tarafından teşvik edilen toksisiteye karşı ısırgan otu özütünün koruyucu rolünün araştırılması,” focused on evaluating the protective effects of nettle extract against paraben-induced toxicity in albino mice. Continuing his studies at the same institution, he earned his Ph.D. in 2022 with a dissertation entitled “Swiss albino farelerde sipermetrin toksisitesinin araştırılması: Fizyolojik, genetik ve biyokimyasal yaklaşım,” supervised by Professor Kültiğin Çavuşoğlu. His doctoral research took a multidisciplinary approach, analyzing cypermethrin-induced toxicity through physiological, biochemical, and genetic methodologies. This comprehensive education has provided Dr. Seven with a solid foundation in experimental biology and toxicology.

Experience

Dr. Baran Seven has contributed to several scientific projects, primarily in the capacity of assistant researcher. His experience includes laboratory-based toxicological studies involving Allium cepa root tip cells and Swiss albino mice. He played a central role in experiments examining the effects of ultraviolet radiation, parabens, heavy metals such as lead, and chemical agents like ammonium sulfate on genetic and physiological parameters. His involvement extended to analyzing the protective effects of natural substances, including Urtica dioica (nettle), Nigella sativa (black seed), carotene, and grape seed extract. Dr. Seven has also explored the antimicrobial and insecticidal properties of Pseudomonas species isolated from wastewater, contributing to the field of microbial biotechnology. He has consistently presented his findings at international and national congresses and has co-authored multiple scientific publications. His expertise spans DNA damage analysis, chromosomal aberration testing, and biochemical assessments, positioning him as a versatile and experienced researcher in biological sciences.

Research Interest

Dr. Baran Seven’s research interests focus on the fields of toxicology, genotoxicity, antioxidant mechanisms, and environmental biology. His primary research aims to evaluate the adverse effects of toxic chemicals such as cypermethrin, parabens, lead nitrate, bisphenol A, and various pesticides on biological systems. He employs animal models, particularly Swiss albino mice, and plant models like Allium cepa, to assess toxicity at genetic, biochemical, and physiological levels. A central theme in his work is the protective potential of natural compounds, including plant extracts and microbial isolates, against chemical-induced genotoxicity and oxidative stress. His methodologies include the use of comet assays, chromosomal aberration analysis, and biochemical marker evaluation to measure DNA damage and cellular response. Dr. Seven’s interdisciplinary approach allows him to contribute meaningfully to both the scientific understanding of toxic substances and the development of potential mitigation strategies using eco-friendly and natural agents.

Awards and Recognition

Although specific individual awards are not explicitly listed, Dr. Baran Seven’s academic profile demonstrates a strong pattern of recognition through conference participation and publication. He has been a consistent contributor to various prestigious scientific meetings, including the International Black Sea Congress on Environmental Sciences, Ecology Symposiums, and the International Anatolian Scientific Research Congress. His role in these conferences has often included presenting full-text research papers and co-authoring collaborative studies, signaling professional acknowledgment from the academic community. Additionally, his ongoing contributions to peer-reviewed journals and collaborative research projects underscore his growing influence in the field. The publication of his doctoral research in high-impact journals, such as Scientific Reports, is a testament to the quality and significance of his work. Dr. Seven’s consistent engagement with both national and international scientific forums indicates a promising academic trajectory and potential for future formal recognitions.

Top Noted Publications

Dr. Baran Seven has authored and co-authored several peer-reviewed articles in national and international journals, emphasizing toxicology, genotoxicity, and microbiology. Key publications include:

Title: Investigation of cypermethrin toxicity in Swiss albino mice with physiological, genetic and biochemical approaches
 Year: 2022
Cited by: 5 articles

Title: Effects of feeding genetically modified (GM) maize on oxidative stress parameters in New Zealand rabbit
 Year: 2018

Title: Insecticidal and Antimicrobial Effects of Pseudomonas Species Isolated From Waste Water
Year: 2022.

Title: Albino Farelerde Paraben Tarafından Oluşturulan Genotoksisitenin Araştırılması: Isırgan Otu Özütünün Koruyucu Rolü
Year: 2017

Conclusion

Dr. Baran Seven is a strong and suitable candidate for the Best Paper Award, especially for his Scientific Reports publication which reflects scientific rigor, interdisciplinary methodology, and public health relevance. His research outputs contribute significantly to the understanding of environmental toxicology and the protective role of natural compounds. With ongoing efforts toward high-impact dissemination and broader scientific visibility, Dr. Seven is poised to make continued valuable contributions to the field.

Weiwei Fu | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Weiwei Fu | Molecular Biology | Best Researcher Award 

Research assistant professor, at Peking University Third Hospital, China.

Dr. Fu Weiwei is an accomplished medical scientist specializing in gastroenterology and immunology. She currently serves as an Assistant Research Professor and Laboratory Director at the Gastroenterology Department, Peking University Third Hospital, where she leads research at the Beijing Key Laboratory. Dr. Fu earned her Ph.D. in Immunology from Peking University Health Science Center and has a strong foundation in traditional medicine, holding a Bachelor of Medicine from Shandong University. With more than a decade of experience in translational medical research, her work bridges cutting-edge immunological discoveries and practical clinical applications. Her focus lies in immune microenvironment dynamics, gastrointestinal tumor evolution, and the integration of traditional Chinese medicine for digestive disease therapies. She has delivered several high-profile international presentations and has published widely in leading scientific journals. Her contributions have significantly advanced the field of digestive immunology.

Professional Profile

Scopus

ORCID

🎓 Education

Dr. Fu’s academic journey began with a 5-year Bachelor of Medicine program at Shandong University of Traditional Chinese Medicine (2002–2007), where she laid a solid foundation in both conventional and traditional healthcare practices. Her early exposure to integrative medicine inspired a unique perspective on digestive health and immune response. Motivated by scientific rigor, she enrolled in the Combined Master’s and Ph.D. Program in Immunology (2008–2013) at Peking University Health Science Center, mentored by Prof. Wenling Han. This elite program sharpened her skills in molecular biology, immunopathology, and clinical translational research. Throughout her doctoral years, she focused on the host immune responses in cancer, particularly those related to gastric inflammation and tumorigenesis. This diverse academic training enables her to merge modern biomedical technologies with traditional insights, giving her an edge in the multidisciplinary field of digestive immunology.

🧪 Experience

Dr. Fu brings a wealth of research and clinical experience to her current position at the Gastroenterology Department, Peking University Third Hospital (2019–present), where she directs the Beijing Key Laboratory. As an Assistant Research Professor, she leads a team focusing on translational immunology in gastrointestinal diseases. Before this, she completed a prestigious postdoctoral fellowship (2013–2019) at the Tsinghua University Institute of Immunology under Prof. Chen Dong, an Academician of the Chinese Academy of Sciences. During this time, she worked on T-cell signaling, immune checkpoints, and the role of lymphoid cells in cancer. Her lab currently integrates clinical cohort data with multi-omics techniques to explore disease mechanisms. She is also instrumental in mentoring junior researchers and clinicians. Her work bridges laboratory immunology with bedside applications, ensuring scientific advancements are translated into improved diagnosis and therapy for patients.

🔬 Research Interests

Dr. Fu’s research centers on the immune microenvironment in gastrointestinal tumors and digestive tract diseases, such as gastric cancer and inflammatory bowel disease. She applies multi-omics technologies—including single-cell RNA sequencing, proteomics, and microbiome analysis—to decipher host-pathogen interactions and immune cell dynamics during disease evolution. A key aspect of her research is understanding how Helicobacter pylori infection initiates gastric lesions, tumor progression, and immune escape. She also investigates traditional Chinese medicine-based therapies, exploring their role in cancer prevention and immune modulation. Another focal point is early screening and biomarker discovery for precancerous lesions through clinical cohort studies. By integrating high-throughput data with clinical insights, her work aims to improve patient stratification and individualized treatments. Her interdisciplinary approach bridges immunology, oncology, and traditional medicine, placing her at the forefront of gastrointestinal research in China and beyond.

🏆 Awards

Dr. Fu’s scientific excellence has been consistently recognized. She won the Outstanding Paper Award at the 2023 Chinese Medical Association’s National Conference on Digestive Diseases (CGC 2023) for her oral presentation on immune profiling during colorectal cancer progression. Her continuous contributions to clinical immunology, translational oncology, and molecular diagnostics have earned her accolades from both national and international platforms. Her selection as an oral presenter at leading conferences—such as DDW 2024 in Washington, D.C., and UEGW 2023 in Copenhagen—speaks to her international recognition. She has also received patent grants for innovations in inflammation and cancer therapy, reflecting her drive for practical applications. As a dedicated researcher, educator, and innovator, Dr. Fu stands out as a top candidate for award nominations in the fields of biomedical research and clinical translational science.

📚 Top Noted Publications

Dr. Fu has authored and co-authored numerous impactful papers in top-tier journals (JCR Q1–Q3), often as first or corresponding author. Below are select publications with hyperlink.

2025

  1. Luteolin Improves Precancerous Gastric Mucosa by Binding STAT3
    International Journal of Biological Sciences (Q1, IF 8.1)
    📌 Co-Corresponding Author
    🧪 Original Research

  2. CMTM3 Regulates Colitis-Associated Cancer Progression
    Cellular and Molecular Gastroenterology and Hepatology (CMGH) (Q1, IF 7.1)
    📌 Co-Corresponding Author
    🧬 Original Research

  3. Cmtm4 Deficiency Exacerbates H. pylori-Induced Gastric Carcinogenesis
    Pathology International (Q2, IF 2.5)
    📌 Co-Corresponding Author
    🦠 Original Research

  4. The Host Immune Response Landscape in Gastric Cancer Development
    Clinical and Experimental Immunology (Q2, IF 3.4)
    📌 First Author
    🧫 Original Research

2024

  1. Neutrophil Heterogeneity in Hepatocellular Carcinoma and Tumor Immunity
    Cancer Medicine (Q2, IF 2.9)
    📌 Co-First Author
    🔬 Original Research

  2. Oxidative Balance in Diet and Sleep Patterns: A Metabolic Interaction
    Frontiers in Nutrition (Q2, IF 4.0)
    📌 Co-First Author
    🍽 Original Research

  3. CMTM4 Facilitates Gastric Cancer Metastasis via EMT Modulation
    Journal of Gastrointestinal Oncology (Q3, IF 2.0)
    📌 Co-First Author
    🧠 Original Research

  4. Cmtm4 Shapes Colitis Outcomes via Microbial Dysbiosis and Mucosal Immunity
    Journal of Genetics and Genomics (Q1, IF 6.6)
    📌 Co-Corresponding Author
    🧪 Original Research

  5. Serum Proteomics-Based Biomarkers of Precancerous Gastric Lesions
    Frontiers in Molecular Biosciences (Q2, IF 3.9)
    📌 Co-Corresponding Author
    🔍 Original Research

  6. Treg Subsets Orchestrate Tumor Microenvironment in Colorectal Cancer
    Frontiers in Immunology (Q1, IF 5.7)
    📌 Co-First & Corresponding Author
    🧫 Original Research

2023

  1. Helicobacter pylori and Inflammasome Activation in Gastric Pathogenesis (Review)
    Helicobacter (Q2, IF 4.3)
    📌 Co-Corresponding Author
    🧯 Review Article

2022

  • Lymphocyte Profile Alterations in Precancerous Gastric Lesions
    Journal of Leukocyte Biology (Q2, IF 5.5)
    📌 First Author
    🧬 Original Research

  • B7 Family Molecules and Immune Evasion in H. pylori Infection (Review)
    Helicobacter (Q2, IF 4.4)
    📌 Co-Corresponding Author
    🧫 Review Article

Conclusion

Dr. FU Weiwei demonstrates an exceptional and well-rounded profile as a medical researcher with significant contributions to immunology and gastroenterology, supported by prestigious academic training, a robust scientific publication record, impactful patents, and strong conference presence. These achievements, particularly in translational cancer immunology, make Dr. Fu highly suitable for the Best Researcher Award.